Breast Cancer New Reference: Inavolisib with Palbociclib and Fulvestrant for Advanced ER+ Breast Cancer Ulas D. Bayraktar, MD 2025-06-02
Prostate Cancer New Reference: Enzalutamide with Radium-223 for Prostate Cancer Ulas D. Bayraktar, MD 2025-06-02
Bladder Cancer New Reference: Enfortumab Vedotin + Pembrolizumab for Advanced Urothelial Carcinoma Ulas D. Bayraktar, MD 2025-06-02
Colorectal Cancer New Reference: Encorafenib, Cetuximab with FOLFOX for bRAF Mutated Metastatic Colorectal Cancer Ulas D. Bayraktar, MD 2025-06-02
Multiple Myeloma New Indication: Daratumumab for High-Risk Smoldering Myeloma Ulas D. Bayraktar, MD 2025-06-02
Bladder Cancer New Protocol: Maintenance Sacituzumab Govitecan with Avelumab for Urothelial Carcinoma Ulas D. Bayraktar, MD 2025-06-02
Follicular Lymphoma New Reference: RiTUXimab alone for Follicular Lymphoma Ulas D. Bayraktar, MD 2025-05-05
GastroEsophageal Cancer New Protocol: TFOX for Advanced Gastric Cancer Ulas D. Bayraktar, MD 2025-05-05
Non-Small Cell Lung Cancer New Reference: Zongertinib for her2 Mutated NSCLC Ulas D. Bayraktar, MD 2025-05-05
Bladder Cancer New Indication: Neoadjuvant Durvalumab with CISplatin/Gemcitabine for Upper GU Tract Cancer Ulas D. Bayraktar, MD 2025-05-05
